Get started
Astellas Pharma, Inc.Astellas Pharma, Inc.Astellas Pharma, Inc.

Astellas Pharma, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

ALPMF chart


Full chart

ALPMF upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪20.08 B‬ USD
Dividend yield (indicated)
4.73%
Price to earnings Ratio (TTM)
35.03
Basic EPS (TTM)
0.32 USD
Net income (FY)
‪338.28 M‬ USD
Revenue (FY)
‪12.75 B‬ USD
Shares float
‪1.71 B‬
Beta (1Y)
0.61

Employees


Employees (FY)
‪13.64 K‬
Change (1Y)
‪−1.11 K‬ −7.53%
Revenue / Employee (1Y)
‪934.37 K‬ USD
Net income / Employee (1Y)
‪24.80 K‬ USD

About ASTELLAS PHARMA


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Naoki Okamura
Website
astellas.com
Headquarters
Tokyo
Founded
1923
ISIN
JP3942400007
FIGI
BBG000BVKB38
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products: XTANDI, PADCEV, XOSPATA, VYLOY, VEOZAH, IZERVAY, EVRENZO, BETANIS and PROGRAF. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.

Check out other big names from the same industry as ALPMF.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ALPMF news



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ALPMF is 11.10 USD — it has increased by 3.74% in the past 24 hours. Watch Astellas Pharma, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Astellas Pharma, Inc. stocks are traded under the ticker ALPMF.
ALPMF stock has risen by 6.12% compared to the previous week, the month change is a 17.34% rise, over the last year Astellas Pharma, Inc. has showed a 2.78% increase.
We've gathered analysts' opinions on Astellas Pharma, Inc. future price: according to them, ALPMF price has a max estimate of 14.85 USD and a min estimate of 8.77 USD. Watch ALPMF chart and read a more detailed Astellas Pharma, Inc. stock forecast: see what analysts think of Astellas Pharma, Inc. and suggest that you do with its stocks.
ALPMF reached its all-time high on Mar 11, 2014 with the price of 63.15 USD, and its all-time low was 8.40 USD and was reached on Apr 11, 2025. View more price dynamics on ALPMF chart.
See other stocks reaching their highest and lowest prices.
ALPMF stock is 3.60% volatile and has beta coefficient of 0.61. Track Astellas Pharma, Inc. stock price on the chart and check out the list of the most volatile stocks — is Astellas Pharma, Inc. there?
Today Astellas Pharma, Inc. has the market capitalization of ‪19.97 B‬, it has increased by 1.99% over the last week.
Yes, you can track Astellas Pharma, Inc. financials in yearly and quarterly reports right on TradingView.
Astellas Pharma, Inc. is going to release the next earnings report on Oct 29, 2025. Keep track of upcoming events with our Earnings Calendar.
ALPMF earnings for the last quarter are 0.27 USD per share, whereas the estimation was 0.14 USD resulting in a 92.33% surprise. The estimated earnings for the next quarter are 0.19 USD per share. See more details about Astellas Pharma, Inc. earnings.
Astellas Pharma, Inc. revenue for the last quarter amounts to ‪3.51 B‬ USD, despite the estimated figure of ‪3.15 B‬ USD. In the next quarter, revenue is expected to reach ‪3.25 B‬ USD.
ALPMF net income for the last quarter is ‪474.78 M‬ USD, while the quarter before that showed ‪499.26 M‬ USD of net income which accounts for −4.90% change. Track more Astellas Pharma, Inc. financial stats to get the full picture.
Astellas Pharma, Inc. dividend yield was 5.12% in 2024, and payout ratio reached 261.05%. The year before the numbers were 4.26% and 736.46% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Aug 13, 2025, the company has ‪13.64 K‬ employees. See our rating of the largest employees — is Astellas Pharma, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Astellas Pharma, Inc. EBITDA is ‪3.53 B‬ USD, and current EBITDA margin is 23.78%. See more stats in Astellas Pharma, Inc. financial statements.
Like other stocks, ALPMF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Astellas Pharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Astellas Pharma, Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Astellas Pharma, Inc. stock shows the neutral signal. See more of Astellas Pharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.